Copyright Reports & Markets. All rights reserved.

Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of ESR1 Mutated Metastatic Breast Cancer Diagnostics by Type
    • 1.3.1 Overview: Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Consumption Value Market Share by Type in 2025
    • 1.3.3 NGS Based
    • 1.3.4 PCR Based
  • 1.4 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market by Application
    • 1.4.1 Overview: Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital Associated Labs
    • 1.4.3 lndependent Diagnostic Laboratories
    • 1.4.4 Diagnostic Imaging Centers
    • 1.4.5 Cancer Research lnstitutes
  • 1.5 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size & Forecast
  • 1.6 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size and Forecast by Region
    • 1.6.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region, (2021-2032)
    • 1.6.3 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size and Prospect (2021-2032)
    • 1.6.4 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size and Prospect (2021-2032)
    • 1.6.6 South America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 APIS Assay Technologies
    • 2.1.1 APIS Assay Technologies Details
    • 2.1.2 APIS Assay Technologies Major Business
    • 2.1.3 APIS Assay Technologies ESR1 Mutated Metastatic Breast Cancer Diagnostics Product and Solutions
    • 2.1.4 APIS Assay Technologies ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 APIS Assay Technologies Recent Developments and Future Plans
  • 2.2 lllumina, Inc.
    • 2.2.1 lllumina, Inc. Details
    • 2.2.2 lllumina, Inc. Major Business
    • 2.2.3 lllumina, Inc. ESR1 Mutated Metastatic Breast Cancer Diagnostics Product and Solutions
    • 2.2.4 lllumina, Inc. ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 lllumina, Inc. Recent Developments and Future Plans
  • 2.3 GENCURIX
    • 2.3.1 GENCURIX Details
    • 2.3.2 GENCURIX Major Business
    • 2.3.3 GENCURIX ESR1 Mutated Metastatic Breast Cancer Diagnostics Product and Solutions
    • 2.3.4 GENCURIX ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 GENCURIX Recent Developments and Future Plans
  • 2.4 RainSure Scientific
    • 2.4.1 RainSure Scientific Details
    • 2.4.2 RainSure Scientific Major Business
    • 2.4.3 RainSure Scientific ESR1 Mutated Metastatic Breast Cancer Diagnostics Product and Solutions
    • 2.4.4 RainSure Scientific ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 RainSure Scientific Recent Developments and Future Plans
  • 2.5 NeoGenomics Laboratories
    • 2.5.1 NeoGenomics Laboratories Details
    • 2.5.2 NeoGenomics Laboratories Major Business
    • 2.5.3 NeoGenomics Laboratories ESR1 Mutated Metastatic Breast Cancer Diagnostics Product and Solutions
    • 2.5.4 NeoGenomics Laboratories ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 NeoGenomics Laboratories Recent Developments and Future Plans
  • 2.6 Sysmex Corporation
    • 2.6.1 Sysmex Corporation Details
    • 2.6.2 Sysmex Corporation Major Business
    • 2.6.3 Sysmex Corporation ESR1 Mutated Metastatic Breast Cancer Diagnostics Product and Solutions
    • 2.6.4 Sysmex Corporation ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Sysmex Corporation Recent Developments and Future Plans
  • 2.7 ASURAGEN,INC
    • 2.7.1 ASURAGEN,INC Details
    • 2.7.2 ASURAGEN,INC Major Business
    • 2.7.3 ASURAGEN,INC ESR1 Mutated Metastatic Breast Cancer Diagnostics Product and Solutions
    • 2.7.4 ASURAGEN,INC ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 ASURAGEN,INC Recent Developments and Future Plans
  • 2.8 Guardant Health
    • 2.8.1 Guardant Health Details
    • 2.8.2 Guardant Health Major Business
    • 2.8.3 Guardant Health ESR1 Mutated Metastatic Breast Cancer Diagnostics Product and Solutions
    • 2.8.4 Guardant Health ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Guardant Health Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of ESR1 Mutated Metastatic Breast Cancer Diagnostics by Company Revenue
    • 3.2.2 Top 3 ESR1 Mutated Metastatic Breast Cancer Diagnostics Players Market Share in 2025
    • 3.2.3 Top 6 ESR1 Mutated Metastatic Breast Cancer Diagnostics Players Market Share in 2025
  • 3.3 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market: Overall Company Footprint Analysis
    • 3.3.1 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market: Region Footprint
    • 3.3.2 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market: Company Product Type Footprint
    • 3.3.3 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Consumption Value by Type (2021-2032)
  • 6.2 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2021-2032)
  • 6.3 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country
    • 6.3.1 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Consumption Value by Country (2021-2032)
    • 6.3.2 United States ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size and Forecast (2021-2032)
    • 6.3.3 Canada ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Consumption Value by Type (2021-2032)
  • 7.2 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Consumption Value by Application (2021-2032)
  • 7.3 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country
    • 7.3.1 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Consumption Value by Country (2021-2032)
    • 7.3.2 Germany ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size and Forecast (2021-2032)
    • 7.3.3 France ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size and Forecast (2021-2032)
    • 7.3.5 Russia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size and Forecast (2021-2032)
    • 7.3.6 Italy ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region
    • 8.3.1 Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Consumption Value by Region (2021-2032)
    • 8.3.2 China ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size and Forecast (2021-2032)
    • 8.3.3 Japan ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size and Forecast (2021-2032)
    • 8.3.5 India ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size and Forecast (2021-2032)
    • 8.3.7 Australia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America ESR1 Mutated Metastatic Breast Cancer Diagnostics Consumption Value by Type (2021-2032)
  • 9.2 South America ESR1 Mutated Metastatic Breast Cancer Diagnostics Consumption Value by Application (2021-2032)
  • 9.3 South America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country
    • 9.3.1 South America ESR1 Mutated Metastatic Breast Cancer Diagnostics Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country
    • 10.3.1 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size and Forecast (2021-2032)
    • 10.3.4 UAE ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Drivers
  • 11.2 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Restraints
  • 11.3 ESR1 Mutated Metastatic Breast Cancer Diagnostics Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Chain
  • 12.2 ESR1 Mutated Metastatic Breast Cancer Diagnostics Upstream Analysis
  • 12.3 ESR1 Mutated Metastatic Breast Cancer Diagnostics Midstream Analysis
  • 12.4 ESR1 Mutated Metastatic Breast Cancer Diagnostics Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global ESR1 Mutated Metastatic Breast Cancer Diagnostics market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    This report is a detailed and comprehensive analysis for global ESR1 Mutated Metastatic Breast Cancer Diagnostics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global ESR1 Mutated Metastatic Breast Cancer Diagnostics market size and forecasts, in consumption value ($ Million), 2021-2032
    Global ESR1 Mutated Metastatic Breast Cancer Diagnostics market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global ESR1 Mutated Metastatic Breast Cancer Diagnostics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global ESR1 Mutated Metastatic Breast Cancer Diagnostics market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for ESR1 Mutated Metastatic Breast Cancer Diagnostics
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global ESR1 Mutated Metastatic Breast Cancer Diagnostics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include APIS Assay Technologies, lllumina, Inc., GENCURIX, RainSure Scientific, NeoGenomics Laboratories, Sysmex Corporation, ASURAGEN,INC, Guardant Health, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    ESR1 Mutated Metastatic Breast Cancer Diagnostics market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    NGS Based
    PCR Based
    Market segment by Application
    Hospital Associated Labs
    lndependent Diagnostic Laboratories
    Diagnostic Imaging Centers
    Cancer Research lnstitutes
    Market segment by players, this report covers
    APIS Assay Technologies
    lllumina, Inc.
    GENCURIX
    RainSure Scientific
    NeoGenomics Laboratories
    Sysmex Corporation
    ASURAGEN,INC
    Guardant Health
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe ESR1 Mutated Metastatic Breast Cancer Diagnostics product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of ESR1 Mutated Metastatic Breast Cancer Diagnostics, with revenue, gross margin, and global market share of ESR1 Mutated Metastatic Breast Cancer Diagnostics from 2021 to 2026.
    Chapter 3, the ESR1 Mutated Metastatic Breast Cancer Diagnostics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and ESR1 Mutated Metastatic Breast Cancer Diagnostics market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of ESR1 Mutated Metastatic Breast Cancer Diagnostics.
    Chapter 13, to describe ESR1 Mutated Metastatic Breast Cancer Diagnostics research findings and conclusion.

    Buy now